top of page
Search

Introducing Somnoril™, a Functional Ingredient for Better Sleep, Weight Loss and Metabolic Wellness


New clinical research demonstrates Somnoril helps people fall asleep faster, sleep better and longer, wake easier and increase daytime activity


Fairfield, CA – June 25, 2024 – Gateway Health Alliances announced today the launch of Somnoril™, an innovative B2B dietary supplement ingredient that is clinically proven to enhance restorative sleep, promote sustainable weight loss, and improve metabolic wellness.


A newly published randomized clinical study in Medical Research Archives shows Somnoril significantly improves multiple aspects of sleep quality and increases daytime energy and activity. Somnoril is a patented extract of Dichrostachys glomerata, which has a long history of use as a culinary spice and traditional medicine in its native West Africa. Four previous randomized clinical trials involving ~550 subjects demonstrate Dichrostachys glomerata enables significant weight loss without diet or exercise and improves metabolic balance and wellness.

 

“Somnoril is a first-of-its-kind natural ingredient that can help consumers address three global health concerns: sleep, healthy weight loss, and metabolic wellness,” said Shil Kothari, President of Gateway Health Alliances. “Our latest research extends the clinically validated weight management benefits of Dichrostachys glomerata to include improvement of sleep quality and quantity for individuals experiencing poor sleep.”

 

Clinical and preclinical research demonstrate that Dichrostachys glomerata, a plant rich in flavonoids, phenolic compounds, alkaloids, tannins, saponins, and terpenoids, is an effective antioxidant that reduces oxidative stress. Poor sleep is often linked to oxidative stress, leading researchers to believe that this is why Somnoril improves sleep quality.

 

Compelling Clinical Results Highlight Sleep Benefits

A recent double-blind, placebo-controlled study was conducted with 56 adults (median age 44) who experienced poor sleep, although not clinically diagnosed. Participants were randomized into either the Dichrostachys glomerata group (receiving 300 mg/day) or the placebo group for 60 days. Sleep outcomes were assessed using the validated self-reported Insomnia Severity Index. Objective measurements of sleep and daytime activity were gathered via Oura Rings. Study analysis was conducted at three time points: Day 0 (baseline), Day 30, and Day 60.

 

The study results include:

 

  • Better Overall Sleep. Subjects taking Somnoril experienced a significant improvement in overall sleep score from the beginning of the study to Day 60. The improvement was seen in both their baseline scores and in comparison to the placebo group.

 

  • Reduced Insomnia Symptoms. The Somnoril group had a 25.6% reduction in insomnia symptoms from the start of the study to Day 60, as measured by the Insomnia Severity Index.

 

  • Increased Deep Sleep. Both the Somnoril and placebo groups experienced significant improvements in deep sleep, but the Somnoril group saw more improvement over time.

 

  • Improved Sleep Efficiency. Somnoril participants showed significant improvement in sleep efficiency throughout the study, spending less time awake in bed.

 

  • Falling Asleep Faster. Subjects in the Somnoril group fell asleep 19.7% faster over the 60-day study period, while the time required for the placebo group to fall asleep increased by 9%.

 

  • Longer Sleep Duration. The Somnoril group experienced significant improvement in sleep duration at both time points in the study, while the placebo group experienced a decrease in sleep duration from the start to Day 60.

 

  • Less Awake Time. The Somnoril group showed a significant improvement in reducing time spent awake in bed from the start of the study to Day 60.

 

  • Increased Total Sleep. Participants increased their total sleep time significantly throughout the study, including light, REM, and deep sleep. In contrast, the placebo group decreased their total sleep time from the beginning to Day 60.

 

  • Improved Activity Levels. The Somnoril group showed increased activity from the beginning to Day 60, while the placebo group experienced a decrease in activity. Somnoril participants also maintained higher levels of activity throughout the study, as measured by the Activity Score and Stay Active scores.

 

“The qualitative results aligned with the objective measures of sleep quality and quantity, as well as daily activity levels,” said Heather A. Hausenblas, Ph.D., lead study author and Professor, School of Applied Health Sciences, Brooks Rehabilitation College of Healthcare Sciences at Jacksonville University. “This demonstrates that the study findings are robust and consistent, providing a more holistic understanding of the participants' experiences.”

 

Weight Management & Metabolic Wellness Clinical Studies

Gateway Health Alliances has conducted four randomized clinical trials involving approximately 550 subjects, as well as safety and toxicology studies, that demonstrate the safety and efficacy of Dichrostachys glomerata (DG) for healthy weight management and metabolic wellness.

 

In one randomized, double-blind, placebo-controlled clinical study, 297 obese men and women (BMI 30-40) consumed 200 mg of DG or a placebo twice daily for eight weeks. Measurements of 16 parameters, including biochemical, body weight and composition, were taken at baseline and after four and eight weeks of supplementation. The DG group showed statistically significant improvements by all measures at every point in the study. After eight weeks, the DG group:

 

  • Lost an average of 24.5 lbs.

  • Reduced body fat an average of 10.7 lbs.

  • Trimmed waist and hip circumferences 10.2% and 7.1%, respectively.

 

The body weight and composition changes coincided with improvements in key biochemical parameters (blood glucose, triglycerides, insulin, adiponectin, C-reactive protein and cholesterol) and improved blood pressure. These results and other studies support the ability of DG to restore to healthy levels multiple biological responses that govern metabolic wellness and weight management.

 

Dichrostachys glomerata: A Potent Antioxidant

Gateway has utilized 10 different testing methods to demonstrate the effectiveness of Dichrostachys glomerata as an antioxidant. The company has also evaluated three extraction methods to identify the most bioactive option. “Not all antioxidants are equal,” said Kothari. “It is important to assess antioxidant activity through multiple test models because antioxidants work through various mechanisms.”

 

About Gateway Health Alliances

Gateway Health Alliances provides food, beverage and supplement manufacturers around the world with natural, science-based ingredients for effective weight management. Founded in 2005, the company is dedicated to the discovery and development of ingredient solutions that can help people enjoy healthier lives. Gateway’s branded ingredients, which are protected by more than 25 patents and patents pending, support healthy weight management, cardiovascular health, metabolic wellness and blood sugar balance.

 

The company also markets a Dichrostachys glomerata product for weight loss under the brand names Dyglomera® and DygloFit®.

 

All Gateway ingredients are sustainably sourced, made in accordance with quality manufacturing standards and validated for purity and authenticity through Purity IQ and other quantitative analytical methods.

 

Contact:

David Walsh

Communications Consultant

Gateway Health Alliances

651-503-8248



Gateway Health Alliances Launches Sleep Supplement ingredient Somnoril 6-25-2024
.pdf
Download PDF • 247KB

 

Comments


Commenting has been turned off.
bottom of page